Arthneeti
All Q2 FY27 results →
AD

Akums Drugs & Pharmaceuticals Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Akums Drugs & Pharmaceuticals Q2 Results 2026 (FY27): Revenue ₹1,342 Cr, Operating margin 14.5%

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Price₹732
Market cap₹11.5K Cr
P/E37.8
Updated2 Nov 2026
Read3 min read

Based on Akums Drugs & Pharmaceuticals Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

Q2 FY27 revenue reported at ₹1,342 crore, up 31.9% YoY from ₹1,018 crore in Q2 FY26 (Page 12, 10). Q2 FY27 EBITDA: INR 195 Cr, margin 14.5%, +106.1% YoY (Page 12) - Q2 FY27 Operating Margin (EBITDA margin): 14.5% (Page 12) - Q2 FY27 Profit After Tax (PAT): INR 115 Cr, margin 8.4%, +168.3% YoY (Pages 9, 10, 12) - Revenue for Q2 FY27: INR 1,342 Cr, +31.9% YoY (Page 12)

From Akums Drugs & Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 2 Nov 2026.

Revenue & Sales Performance

  • Q2 FY27 revenue reported at ₹1,342 crore, up 31.9% YoY from ₹1,018 crore in Q2 FY26 (Page 12, 10).
  • Volume growth is highlighted as double digit in the CDMO segment (Page 9, 4).
  • CDMO segment revenue share: 83.1% for Q2 FY27 (Page 10).
  • Domestic branded formulation revenue grew by 8% YoY (Page 4).
  • International branded formulations showed accelerating growth both YoY and QoQ (Page 4).
  • Trade generics segment achieved EBITDA positivity; API segment continues towards profitability (Pages 4, 9).
  • Sequential QoQ revenue growth in Q2 FY27 was 15.1% (Page 12).

2 more points from Akums Drugs & Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Akums Drugs & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Roorkee and Noida facilities (2026) focused on Cosmeceuticals with capacities of 13 Cr and 7 Cr units respectively.
  • Zambia initiative: commercial supplies from Indian plant scheduled in Q4 FY27, with revenue recognition expected in Q1 FY28.
  • Established several plants in Haridwar, Kotdwar, Baddi, Noida, and Roorkee between 2004 and 2027 covering various dosage forms and capacities ranging from 2 Cr to 2,635 Cr units annually.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Akums Drugs & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Akums Drugs & Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.

Akums Drugs & Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.3K Cr, net profit ₹115 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Akums Drugs's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Wockhardt Ltd (Q2 FY27)

    969 crore, up from Rs. Key results statement takeaways from Wockhardt Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • JFL Life (Q2 FY27)

    This represents a year-on-year increase of approximately 96% in revenue for the quarter. Key results statement takeaways from JFL Life Sciences Ltd's Q2 FY27 ea

  • P & G Health Ltd (Q2 FY27)

    Revenue from Operations for the quarter ended September 30, 2026, is ₹38,249 lakhs (Page 4). Key results statement takeaways from Procter & Gamble Health Ltd's

  • Sai Parenteral's (Q2 FY27)

    Q2FY27 Revenue from Operations: ₹196.1 crore, up 257.4% YoY from ₹54.9 crore in Q2FY26 (Page 56). Key investor presentation takeaways from Sai Parenterals Ltd's

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Akums Drugs & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Akums Drugs & Pharmaceuticals Ltd Q2 FY27 results?

Q2 FY27 revenue reported at ₹1,342 crore, up 31.9% YoY from ₹1,018 crore in Q2 FY26 (Page 12, 10). Q2 FY27 EBITDA: INR 195 Cr, margin 14.5%, +106.1% YoY (Page 12) - Q2 FY27 Operating Margin (EBITDA margin): 14.5% (Page 12) - Q2 FY27 Profit After Tax (PAT): INR 115 Cr, margin 8.4%, +168.3% YoY (Pages 9, 10, 12) - Revenue for Q2 FY27: INR 1,342 Cr, +31.9% YoY (Page 12)

What is Akums Drugs & Pharmaceuticals Ltd share price analysis?

Akums Drugs & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 37.8 with a market cap of ₹11,517 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Akums Drugs & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.